morphine sulfate + docusate + senna

This combination therapy protocol consists of a low-dose, extended-release formulation of morphine sulfate co-administered with a prophylactic laxative regimen of docusate and senna. Developed and evaluated by Flinders University, specifically in the Phase III BEAMS trial, this intervention is intended for the management of chronic refractory breathlessness (dyspnea) in patients with advanced chronic obstructive pulmonary disease (COPD). Morphine sulfate acts as an agonist at the mu-opioid receptor, which is thought to alleviate the sensation of breathlessness by modulating the central perception of respiratory distress and reducing the ventilatory response to physiological triggers. The inclusion of docusate (a stool softener) and senna (a stimulant laxative) is a standard clinical measure to prevent and manage opioid-induced constipation, a common and dose-limiting side effect of morphine, thereby improving the overall tolerability and safety of the treatment in chronic care settings.

Other names

low-dose extended-release morphine + laxativemorphine sulfate + docusate sodium + sennasustained-release morphine sulfate + docusate with senna